ID   H69R
AC   CVCL_RS65
DR   cancercelllines; CVCL_RS65
DR   Wikidata; Q54872207
RX   PubMed=27610620;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1579 ! NCI-H69
SX   Male
AG   55Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 11
//
RX   PubMed=27610620; DOI=10.1371/journal.pone.0162925; PMCID=PMC5017656;
RA   Yan F., Pang J.-X., Peng Y., Molina J.R., Yang P., Liu S.-J.;
RT   "Elevated cellular PD1/PD-L1 expression confers acquired resistance to
RT   cisplatin in small cell lung cancer cells.";
RL   PLoS ONE 11:E0162925-E0162925(2016).
//